Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Molecular Partners AG
  6. News
  7. Summary
    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Options of Molecular Partners AG are subject to a Lock-Up Agreement Ending on 14-SEP-2021.

09/14/2021 EDT

Certain Options of Molecular Partners AG are subject to a Lock-Up Agreement Ending on 14-SEP-2021. These Options will be under lockup for 91 days starting from 15-JUN-2021 to 14-SEP-2021. Details: The directors, executive officers, and certain shareholders, or the lock-up parties, have entered into lock up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus (such period, the “restricted period”), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC, SVB Leerink LLC and Cowen and Company, LLC, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, grant instruction rights (Weisungsrechte) pursuant to article 25 of the Swiss Federal Intermediated Securities Act or otherwise transfer or dispose of, directly or indirectly, any shares of common shares, ADSs or any securities convertible into or exercisable or exchangeable for common shares or ADSs (including, without limitation, common shares, ADSs or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common shares and ADSs, the “lock-up securities”)), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the lock-up securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of lock-up securities, in cash or otherwise, (3) make any demand for, or exercise any right with respect to, the registration of any lock-up securities, or (4) publicly disclose the intention to do any of the foregoing. Such persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (by any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any lock-up securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of lock-up securities, in cash or otherwise.


© S&P Capital IQ 2021
All news about MOLECULAR PARTNERS AG
10/20MOLECULAR PARTNERS : Pre-clinical data of ensovibep, a multi-specific DARPin therapeutic w..
PU
10/20MOLECULAR PARTNERS : Says Drug Prevents Infection from COVID-19 Variants
MT
10/20MOLECULAR PARTNERS : Says Preclinical Data Show Ensovibep's Potency Against COVID-19 Viral..
MT
10/20MOLECULAR PARTNERS : Present Data Demonstrating Successful Inhibition of COVID19 Viral Var..
AQ
10/01ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
09/14Certain Common Shares of Molecular Partners AG are subject to a Lock-Up Agreement Endin..
CI
09/14Certain Options of Molecular Partners AG are subject to a Lock-Up Agreement Ending on 1..
CI
09/14Certain Restricted Share Units of Molecular Partners AG are subject to a Lock-Up Agreem..
CI
09/14Certain Performance Share Units of Molecular Partners AG are subject to a Lock-Up Agree..
CI
09/10MOLECULAR PARTNERS : MP Corporate Presentation
PU
More news
Analyst Recommendations on MOLECULAR PARTNERS AG
More recommendations
Financials
Sales 2021 52,5 M 57,3 M 57,3 M
Net income 2021 -16,2 M -17,6 M -17,6 M
Net cash 2021 119 M 130 M 130 M
P/E ratio 2021 -31,8x
Yield 2021 -
Capitalization 585 M 638 M 638 M
EV / Sales 2021 8,87x
EV / Sales 2022 7,79x
Nbr of Employees 158
Free-Float 77,5%
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 18,12 CHF
Average target price 27,41 CHF
Spread / Average Target 51,3%
EPS Revisions
Managers and Directors
Patrick Amstutz Chief Executive Officer & Director
Andreas Emmenegger Chief Financial Officer
William Matt Burns Chairman
Daniel Steiner Senior Vice President-Research
Nicolas Leupin Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MOLECULAR PARTNERS AG-12.67%638
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610